Primary inflammatory disease in heart failure with preserved ejection fraction

31 August 2024 (10:00 - 10:50)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Doctor Atsushi Tada

Mayo Clinic, Rochester (United States of America)

8 More presentations in this session

Presentation thumbnail

Delays in diagnosis and treatment initiation of ATTR cardiac amyloidosis: a real-world data analysis

Doctor J. Vogel (Essen, DE)

Abstract Slides Video

Presentation thumbnail

Transthyretin stabiliser therapy in patients with transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis

Mr V. Ribeiro (Teresina, BR)

Abstract Slides Video

Presentation thumbnail

Prevalence of transthyretin amyloid cardiomyopathy in patients hospitalised for heart failure with preserved ejection fraction in an LATAM center.

Mr S. Decotto (Buenos Aires, AR)

Abstract Slides Video

Presentation thumbnail

Biomarkers for monitoring patients with cardiac amyloidosis during transthyretin-stabilizer therapy

Doctor J. Vogel (Essen, DE)

Abstract Slides

Presentation thumbnail

Relationship between changes in renal function after acute phase of tafamidis administration and left ventricular diastolic function at mid-term follow-up in transthyretin cardiac amyloidosis

Ms A. Senda (Kobe, JP)

Abstract Slides

Access the full session

Session thumbnail

Cardiac amyloidosis, sarcoidosis, and inflammation

The Event

Event poster

ESC Congress 2024

31 August 2024 10:00 CET

You may be interested in

Congress Presentation

Impact of systemic inflammation on exercise hemodynamics in unexplained dyspnea and heart failure with preserved ejection fraction

Congress Presentation

Inflammation in heart failure with preserved ejection fraction

Congress Presentation

New trends in pathophysiology

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources